

## **CHANGE OF REGISTERED OFFICE**

**Perth, Australia; 30 JUNE 2021** - Argenica Therapeutics Limited (ASX: AGN) ("Argenica" or the "Company") advises in accordance with ASX Listing Rule 3.14 that its registered office and principal place of business address has changed with immediate effect to:

4/117 Broadway Nedlands WA 6009.

All other contact details remain the same.

This announcement has been approved for release by the Board of Argenica

For more information please contact: info@argenica.com.au

## **ABOUT ARGENICA**

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain damage after stroke and improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicity before commencing Phase 1 clinical trials in humans. The aim is for our therapeutic to be administered by first responders to protect brain tissue against damage during a stroke with further potential to enhance recovery once a stroke has taken place.

1. Gorelick PB. "The global burden of stroke: persistent and disabling". Lancet Neurol. 2019 May;18(5):417-418

